| Study 01 – Genetics of Opioid Dependence | Joel Gelernter | Opioid-Cocaine Dependence | Available at NIDA |
| Study 02 – Mapping Susceptibility Genes for Nicotine Dependence | Ming D. Li | Nicotine Dependence | Available at NIDA |
| Study 03 – Molecular Genetics of Heroin Dependence in China | Ming Tsuang | Opioid Dependence | Available at NIDA and dbGaP |
| Study 05 – Addictions, Genotypes, Polymorphisms, and Function | MaryJeanne Kreek | Opioid Dependence | Available at NIDA and dbGaP |
| Study 06 – The Genetics of Vulnerability to Nicotine | Pamela Madden | Nicotine Dependence | Available at NIDA and dbGaP |
| Study 07 – An Introduction to the Family Study of Cocaine | Laura Bierut | Cocaine Dependence | Available at NIDA |
| Study 08 – Mu Opioid Receptor Gene in Heroin Addicts | Lei Yu | Opioid Dependence | Available at NIDA |
| Study 09 – Differentiation of Phenotypes for Smoking: Administrative Supplement to Join NIDA Genetics Consortium | Ovide Pomerleau | Nicotine Dependence | Available at NIDA |
| Study 10 – Pharmacokinetics of Nicotine in Twins | Gary Swan | Nicotine Dependence | Available at NIDA |
| Study 11 – Adolescent Drug Dependence | John Hewitt | Polysubstance Dependence | Available at NIDA and dbGaP |
| Study 12 – Substance Abuse and the Dopamine System Genes | Michael M. Yanyukov | Polysubstance Dependence | Available at NIDA |
| Study 13 – Genetics of Cocaine Induced Psychosis | Joseph F. Cubells | Cocaine Dependence | Available at NIDA |
| Study 14 – Genome-Wide Analysis for Addiction Susceptibility Genes | Herb Lachman | Opioid Dependence | Available at NIDA and dbGaP |
| Study 15 – Nicotine Dependence | Laura Bierut | Nicotine Dependence | Available at NIDA |
| Study 16 – Nicotine Dependence | Mark Leppert | Nicotine Dependence | Available at NIDA |
| Study 17 – Opioid Dependence | Wade Berrettini | Opioid Dependence | Available at NIDA and dbGaP |
| Study 18 – Opioid Dependence: Candidate Genes and G x E Effects | Elliot Nelson | Opioid Dependence | Available at NIDA |
| Study 19 – Epidemiological Study of Substance Abuse | Rob Philibert | Polysubstance Dependence | Available at NIDA |
| Study 20 – Innovative Approaches for Cocaine Pharmacotherapy | Henry Kranzler | Opioid-Cocaine Dependence | Available at NIDA |
| Study 21 – Twin Family Study of Vulnerability to Substance Abuse | William Iacono | Polysubstance Dependence | Combined with Study 25 |
| Study 22 – Exploring the Genetic Basis for Drug Use | Hallam Hurt | Polysubstance Dependence | Closed |
| Study 23 – Substance Use Disorder Liability: Candidate Gene System | Michael M. Vanyukov | Polysubstance Dependence | Available at NIDA |
| Study 24 – START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies (START) | Wade Berrettini | Opioid Dependence | Available at NIDA and dbGaP |
| Study 25 – The Genes, Environment, and Development Initiative (GEDI) | William Iacono | Other | Available at dbGaP |
| Study 26 – The Genes, Environment, and Development Initiative (GEDI) | E. Jane Costello | Other | Available at dbGaP |
| Study 27 – The Genetic Study of Nicotine Dependence in African Americans (AAND) | Laura Bierut | Nicotine Dependence | Available at NIDA |
| Study 28 – Center on Antisocial Drug Dependence: the Genetics of HIV Risk Behavior | John Hewitt | Other | TBA |
| Study 29 – Genetics Protocol of the Cocaine Use Reduction with Buprenorphine (CURB) Study; CTN-0048 | David A. Nielsen | Cocaine Dependence | TBA |
| Study 30 – Phase 2: Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Nepicastat for Cocaine Dependence | Thomas R. Kosten | Cocaine Dependence | TBA |
| Study 31 – Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT); CTN-0051 | John Rotrosen | Smokescreen | Available at dbGaP |
| Study 32 – Achieving Cannabis Cessation-Evaluation of N-Acetylcysteine (ACCENT); CTN-0053 | Kevin Gray | Other | TBA |
| Study 33 – Genome-wide Association Study of HIV-1 Host Genetics Among Injection Drug Users | Eric Johnson | Other | Available at dbGaP |
| Study 34 – Attention Deficit-Hyperactivity Disorder (ADHD) | Robert K. Moyzis | Other | TBA |
| Study 35 – Genetically Informative Smoking Cessation Trial | Li-Shiun Chen | Nicotine Dependence | Available at NIDA |
| Study 36 – Genetic Dissection in Pedigrees of Substance Use and Mood Disorders Comorbidity | Nelson B. Freimer | Other | TBA |
| Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder | Madhukar Trivedi | Other | TBA (370 samples will be collected over the next 2 years) |
| Study 38 – Adolescent Brain Cognitive Development (ABCD) Study | | Other | Available at NDA |
| Study 39 – Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT) | Adam Bisaga | Opioid Dependence | TBA |
| Study 40 – Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY) | Gavin Bart | Opioid Dependence | TBA |
| Study 41 – Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy | Edward Nunes | Opioid Dependence | TBA |
| Study 42 – Genetics Analysis of Substance Use Disorder Using the Indiana Biobank Data | Dongbing Lai | Other | TBA |
| Study 43 – Pediatric Imaging, Neurocognition, and Genetics (PING) | Terry Jernigan | Other | TBA |
| Study 44 – Randomized, Placebo-Controlled Trial of Injectable Naltrexone and Monthly Injectable Buprenorphine for Cocaine Use Disorder (CURB-2); CTN-0109 | Madhukar Trivedi | Cocaine Dependence | TBA |
| Study 45 – Randomized, Double-Blind, Placebo-Controlled Trial of Monthly Injectable Buprenorphine for Methamphetamine Use Disorder (MURB); CTN-0110 | Steve Shoptaw | Polysubstance Dependence | TBA |
| Study 46 – Advancing Genomics Research of Substance Use Disorders in Latin American Populations | Janitza Montalvo-Ortiz & Humberto Nicolini | Polysubstance Dependence | TBA |
| Study 51 – Genotyping on Smokescreen Microarray Chip | Jasmin Vassileva & Alexandre Todorov | Smokescreen | Available at dbGaP; dbGaP |
| Study 52 – Genetic Contribution to the Abuse Liability of Oxycodone | Jermaine Jones | Smokescreen | Available at dbGaP |
| Study 53 – The Women’s Interagency HIV Study (WIHS) | Brad Aouizerat | Smokescreen | Available at dbGaP |
| Study 54 – Genotyping on Smokescreen Microarray Chip | Deborah Mash | Smokescreen | Available at dbGaP |
| Study 55 – ALIVE Cohort Smokescreen GWAS | Brion Maher | Smokescreen | Available at dbGaP |
| Study 56 – Assess the Cardiovascular, Cognitive, and Subjective Effects of Atomoxetine in Combination with IV Methamphetamine | Edythe London | Smokescreen | Available at dbGaP |
| Study 57 – Neural Systems, Inhibitory Control, and Methamphetamine Dependence | Edythe London | Smokescreen | Available at dbGaP |
| Study 58 – Early Methamphetamine Abstinence fMRI and Brain Function | Edythe London | Smokescreen | Available at dbGaP |
| Study 59 – Smokescreen; Opioid/Cocaine Use; Antisocial Drug Dependence | Robin Corley | Smokescreen | Available at dbGaP |
| Study 60 – Gene-Environment Interactions in COCCaINE Use Disorder: Collaborative Case-Control Initiative in Cocaine Addiction | Rodrigo Grassi-Oliveira | Smokescreen | Available at dbGaP |
| Study 61 – Smokescreen; NJD/NID Cohort | Stanley Weiss | Smokescreen | Available at dbGaP |
| Study 62 – Prevention of Viral Hepatitis and HIV in Drug Users – A Hepatitis B Model for HIV and an HB Vaccine Model (DASH) | Lu-Yu Hwang | Smokescreen | Available at dbGaP |
| Study 63 – Smokescreen; InC3 Cohort Substance Abusers | Kimberly Page | Smokescreen | Available at dbGaP |
| Study 64 – Smokescreen; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) | Inga Peter | Smokescreen | Available at dbGaP |
| Study 65 – Spit for Science | Danielle Dick | Smokescreen | Available at dbGaP |
